International Journal of Nuclear Medicine Research  (Special Issue - 2017)
 Review of Pharmacoeconomic Studies in Radionuclide Therapy of Painful Bone Metastases Nuclear
Pages 101-106

Voloznev Lev


Published: 31 July 2017

By virtue of the rapid development of nuclear medicine technologies, pharmacoeconomics shall occupy one of the key roles in assessing the applicability of one or another nuclear medicine’s methods in clinical practice. Based on existing evidence, application of the 153Sm-EDTMP and 89SrCl2 S is an economically feasible approach to treat painful bone metastases. Comparing to existing radiopharmaceutical agents intended for therapy of painful bone metastases, radiopharmaceutical agents that have been developed on the basis of generator-produced radionuclide Rhenium 188 (e.g. 188Re-HEDP, 188Re-zoledronic acid), allow to believe in the explicit economic advantage in future when implementing into clinical practice.
Pharmacoeconomics, Zoledronic acid, Bone metastases, Radiopharmaceutical.